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Cinnamon bark is commonly used in traditional Japanese herbal medicines (Kampo
medicines). The coumarin contained in cinnamon is known to be hepatotoxic, and a
tolerable daily intake (TDI) of 0.1 mg/kg/day, has been quantified and used in Europe
to insure safety. Risk assessments for hepatotoxicity by the cinnamon contained in
foods have been reported. However, no such assessment of cinnamon bark has been
reported and the coumarin content of Kampo medicines derived from cinnamon bark is
not yet known. To assess the risk for hepatotoxicity by Kampo medicines, we evaluated
the daily coumarin intake of patients who were prescribed Kampo medicines and
investigated the relation between hepatotoxicity and the coumarin intake. The clinical
data of 129 outpatients (18 male and 111 female, median age 58 years) who had been
prescribed keishibukuryogankayokuinin (TJ-125) between April 2008 and March 2013
was retrospectively investigated. Concurrent Kampo medicines and liver function were
also surveyed. In addition to TJ-125, the patients took some of the other 32 Kampo
preparations and 22 decoctions that include cinnamon bark. The coumarin content of
these Kampo medicines was determined by high performance liquid chromatography
(HPLC). TJ-125 had the highest daily content of coumarin (5.63 mg/day), calculated
from the daily cinnamon bark dosage reported in the information leaflet inserted in each
package of Kampo medicine. The coumarin content in 1g cinnamon bark decoction
was 3.0 mg. The daily coumarin intake of the patients was 0.113 (0.049–0.541)
mg/kg/day, with 98 patients (76.0%) exceeding the TDI. Twenty-three patients had an
abnormal change in liver function test value, but no significant difference was found
in the incidence of abnormal change between the group consuming less than the TDI
value (6/31, 19.4%) and the group consuming equal to or greater than the TDI value
(17/98, 17.3%). In addition, no abnormal change related to cinnamon bark was found
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for individual patients. This paper was done to assess the risk of hepatotoxicity by
the coumarin contained in Kampo medicines and to clarify whether or not the Kampo
preparations in general use that contain cinnamon bark may be safely used in clinical
practice.
Keywords: coumarin, traditional Japanese herbal medicine, hepatotoxicity, tolerable daily intake, cinnamon bark,
high performance liquid chromatography, keishibukuryogankayokuinin
INTRODUCTION
Cinnamon bark is commonly used in traditional Japanese herbal
medicines (Kampo medicines), especially for the treatment of
fever and hot flashes. The coumarin contained in cinnamon
was used as a flavoring ingredient in foods (Egan et al., 1990),
but it was banned from use in food by the Food and Drug
Administration (FDA) of the United States in 1954. The FDA
made the decision based on data from animal studies that used
rats (Egan et al., 1990). A study by Hazleton et al. (1956) indicated
that coumarin is hepatotoxic. Since the 1970s, several studies
have reported that coumarin improves lymphedema (Casley-
Smith et al., 1993a,b), but coumarin related hepatotoxic action
was observed in a clinical study by Loprinzi et al. (1999). Some
papers have reported that cinnamon improves glucose and lipid
metabolism (Khan et al., 2003; Sato et al., 2006), and cinnamon is
used as a dietary supplement.
The German Federal Institute for Risk Assessment (BfR)
established a tolerable daily intake (TDI) value of 0.1 mg
coumarin per kg body weight [BfR (Federal Institute for Risk
Assessment), 2006]. Some reports have determined the coumarin
content of foods and assessed its toxicity (Sproll et al., 2008;
Abraham et al., 2010). It is possible that heavy consumption of
the cinnamon included in cookies, tea, and other cinnamon rich
foods could exceed the TDI, making it important to pay careful
attention to the amount of cinnamon taken in food (Abraham
et al., 2010). A 2015 report was published of a case in which
a patient, after administration of the cholesterol-lowering drug
rosuvastatin, experienced acute hepatitis after taking a cinnamon
supplement (Brancheau et al., 2015).
The main pathway of coumarin metabolism is 7-
hydroxylation leading to detoxification, and the minor pathway
is the metabolism of the lactone ring to form a coumarin
3,4-epoxide intermediate, which can lead to hepatotoxicity
(Lake et al., 1989, 1994). 7-hydroxylation, which is predominant
in humans, is metabolized by CYP2A6 (Shilling et al., 1969;
Cholerton et al., 1992; Pearce et al., 1992; Pelkonen et al., 2000).
The clinical data of patients treated with coumarin showed
that a few percent were sensitive to the hepatotoxic action
(Abraham et al., 2010). It is assumed that the cause of this higher
susceptibility is the genetic polymorphism of CYP2A6 with
deficient 7-hydroxylation of coumarin, which possibly leads to
an increased formation of 3,4-coumarin epoxide. The frequency
of poor metabolizers of CYP2A6 in Asian populations is much
Abbreviations: Alb, albumin; ALP, alkaline phosphatase; ALT, aspartate
aminotransferase; AST, alanine aminotransferase; CTCAE, Common Terminology
Criteria for Adverse Events; FDA, Food and Drug Administration; γ-GTP,
γ-glutamyl transpeptidase; HPLC, high performance liquid chromatography;
T-Bill, total bilirubin; TDI, tolerable daily intake.
higher than that of Caucasian populations (Peamkrasatam et al.,
2006). Unfortunately, the association between hepatotoxicity
and CYP2A6 genetic polymorphism has not been investigated.
In addition, the underlying mechanism(s) of human coumarin-
related hepatotoxicity has not been elucidated (Abraham et al.,
2010).
Cinnamon is generally divided into two types, Ceylon
cinnamon and cassia cinnamon. The coumarin content of cassia
cinnamon is higher than that of Ceylon cinnamon (Wang et al.,
2013). Cassia cinnamon bark is used in traditional Japanese
herbal medicines (Kampo medicines). Kampo medicines are of
two types; one is a preparation composed of the powdered extract
of the herbs specific to each medicine and the other is made
by decoction, the extraction of the water-soluble substances by
boiling the herbs. In general, side effects are rarely caused by
Kampo medicines, but serious hepatotoxicity has been reported
(Teschke et al., 2015). It is possible that Kampo medicines
that contain coumarin cause hepatotoxicity, however, their
coumarin content has not been clarified. Furthermore, the risk
of hepatotoxicity from coumarin contained in Kampo medicines
has not been assessed in clinical practice.
The Kampo preparations keishibukuryogan (TJ-25) and
keishibukuryogankayokuinin (TJ-125) are generally used in
Japan as an alternative for the coumarin derivative warfarin. One
of the reasons is that they are manufactured by extraction from
cinnamon bark. Keishibukuryogan inhibited platelet aggregation
in guinea pig whole blood has been reported (Terawaki et al.,
2015). In clinical studies, keishibukuryogan was reported to
lower blood viscosity, to improve intra-vascular erythrocyte
aggregation (Itoh et al., 1992), and to improve the symptoms
of patients with non-specific complaints associated with varicose
veins of the lower extremities (Hayashi et al., 2014). TJ-125 is
a Kampo preparation that includes the extract of coix seeds. In
clinical practice, we use TJ-125 more frequently than TJ-25 as
alternative for warfarin because TJ-125 contains more cinnamon
bark than TJ-25. For these reasons, we focused on patients who
had been prescribed TJ-125.
The aims of this study were to evaluate the coumarin content
of Kampo medicines derived from cinnamon bark and to assess
the risk for hepatotoxicity from the use of these medicines
in clinical practice. We developed a system for quantitatively
determining the coumarin content of Kampo medicines that uses
high performance liquid chromatography (HPLC) to determine
the risk of hepatotoxicity for patients prescribed TJ-125. Based
on the coumarin content of the Kampo medicines prescribed,
we determined the daily intake of coumarin by patients at two
hospitals. We investigated the frequency of liver dysfunction
during TJ-125 treatment and the possible association between
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hepatotoxicity and the daily intake of coumarin. The importance
of this study is that it clarifies the risk of hepatotoxicity from
Kampo medicines derived from cinnamon bark and that it will
contribute to safer, more effective use of Kampo medicines.
MATERIALS AND METHODS
Subjects
From April 2008 to March 2013, 351 Japanese outpatients were
prescribed TJ-125 at the Kampo Medicine Clinic of Kyushu
University Hospital or Iizuka Hospital. The inclusion criteria
were as follows: (1) no previous history of liver disease; (2) the
body weight was recorded; and (3) examination of liver function
was performed before and after the prescription of TJ-125. After
exclusions, the data of 129 outpatients was available for analysis.
The study was approved by the Ethics Committees of Kyushu
University Hospital and Iizuka Hospital.
Clinical Data Collection
We retrospectively investigated the clinical data of the enrolled
outpatients using their electronic medical records. Precise
information was obtained on age, sex, body weight, the TJ-125
dosing period, daily dosage, concurrent drugs, and liver function
test values: AST, ALT, γ-GTP, ALP, T-Bill, and Alb.
Assessment of Hepatotoxicity
Adverse events associated with the liver were graded from 0
to 5 by the liver function test values according to Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Hepatotoxicity was defined as an abnormal change in a liver
function test value that was increased at two consecutive testing
points during the period of administration of TJ-125. When
abnormal change was observed, we surveyed the dosage of the
Kampo medicines prescribed and the drug history using the
patient’s electronic medical record. The patients’ doctors were
contacted for judgments related to the timing of abnormal
change. The daily intake of coumarin for each patient was
calculated based on the maximum total coumarin content of the
prescribed TJ-125 and any concurrent Kampo medicines taken
during the dosing period with TJ-125. Patients were classified
into two groups: one with less than the TDI value and the
other with equal to or greater than the TDI value. To investigate
the association between TDI and an abnormal change in liver
function, we compared the hepatotoxicity rates of these two
groups.
Materials
Coumarin, acetonitrile (HPLC grade), methanol (HPLC grade),
and trifluoroacetic acid were purchased from Wako Pure
Chemical Industries (Osaka, Japan).
Twenty-five Kampo preparations made with extract granules
were purchased from Tsumura & Co. (Tokyo, Japan): kakkonto
(TJ-1), hachimijiogan (TJ-7), saikokeishito (TJ-10),
saikokeishikankyoto (TJ-11), saikokaryukotsuboreito (TJ-12),
goreisan (TJ-17), keishikajutsubuto (TJ-18), shoseiryuto
(TJ-19), keishibukuryogan (TJ-25), keishikaryukotsuboreito
(TJ-26), maoto (TJ-27), mokuboito (TJ-36), tokishigya-
kukagoshuyushokyoto (TJ-38), ryokeijutsukanto (TJ-39),
keishito (TJ-45), juzentaihoto (TJ-48), goshakusan (TJ-63),
shakanzoto (TJ-64), nyoshinsan (TJ-67), keishininjinto (TJ-82),
jidabokuippo (TJ-89), goshajinkigan (TJ-107), saireito (TJ-
114), tokikenchuto (TJ-123) and keishibukuryogankayokuinin
(TJ-125). Saikokeishito (N10), saikokeishikankyoto (N11),
saikokaryukotsuboreito (N12) and kumibinroto (N311) were
purchased from Kotaro Pharmaceutical Co., Ltd. (Osaka, Japan).
Keishikaryojutsubuto (SG-18R) was purchased from Ohsugi
Pharmaceutical Co., Ltd. (Osaka, Japan). Keishikaogito (TY-026)
was purchased from Toyo Yakuko Co., Ltd. (Tokyo, Japan).
Kakkonkajutsubuto (S-07) was purchased from Sanwa Shoyaku
Co., Ltd. (Tochigi, Japan). Hachimigan was purchased from
Uchida Wakanyaku Co., Ltd. (Tokyo, Japan). The cinnamon
bark used for decoction was purchased from Tochimoto
Tenkaido (Osaka, Japan).
Quantitative Determination of the
Coumarin Used in Kampo Preparations
and in Cinnamon Bark
The coumarin content of the Kampo preparations and cinnamon
bark was determined using HPLC. The Kampo preparations used
were manufactured between 2011 and 2013. The extraction of the
components of the Kampo preparations followed the procedures
of Okamura et al. (1999). Briefly, 0.5 g of the Kampo preparation
was sonicated for 30 min with 30 mL of 65 % methanol, then
centrifuged at 1,500 × g for 10 min. For the cinnamon bark,
20 g of cinnamon bark was heated for 40 min with 600 mL of
water, then centrifuged at 1,500 × g for 20 min. The supernatant
was filtered through a 0.45 µm syringe filter (Merck Millipore,
Darmstadt, Germany) after which 10 µL of solution was injected
into the HPLC system.
The samples tested were from three different production lots,
when possible. In cases for which it was impossible to obtain
Kampo preparations from three production lots, one or two
production lots were tested. After confirming that the extraction
error was less than 3 %, each sample had a single extraction
analyzed in duplicate by HPLC.
The daily dosage was obtained from the information leaflet
inserted in the package of each Kampo preparation. The
coumarin content in the daily dosage was determined by the
mean amount in 1–3 production lots. The coumarin content
in the daily dosage of cinnamon bark was determined by
quantitation analysis using HPLC. The information in the
package states that the standard daily dosage of TJ-125 contains
4 g of cinnamon bark. Therefore, we compared the coumarin
content of TJ-125 with 4 g of cinnamon bark for decoction use.
We then calculated the coumarin content per 1 g of cinnamon
bark contained in the other Kampo medicines.
HPLC Conditions
The HPLC method used to determine the coumarin content of
the different Kampo medicines was modified from that used
for the determination of the (E)-cinnamic acid contained in
keishibukuryogan extract found in the Japanese Pharmacopoeia
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16th Edition (Ministry of Health, Labour and Welfare, Japan,
2011). A Shimadzu LC10A system (Shimadzu Co., Kyoto, Japan)
equipped with a photodiode array detector (SPD-M10AVP) was
used. A Gemini-Nx5u C18 110A column (250 mm × 4.6 mm
I.D., 5 µm, Phenomenex, Torrance, CA, USA) was used with a
mobile phase that consisted of a mixture of water, acetonitrile,
and trifluoroacetic acid (750:250:0.5, v/v/v) delivered at a flow
rate of 0.5 mL/min. The column temperature was maintained at
40◦C. The absorbance detector was set at 273 nm.
Calibration Curve
The standard coumarin solutions were prepared to 0.5, 1, 5,
10, 15, and 20 mg/mL in water-acetonitrile solution (1:1, v/v).
A calibration curve obtained by plotting the peak area versus the
concentration of coumarin, and the quantity of coumarin in the
extraction was determined by use of an absolute calibration curve
method.
Statistical Analysis
Data are shown as mean ± SD or median (range). Statistical
differences between the group consuming less than the TDI
value and the group equal to or greater than the TDI value
were evaluated using Fisher’s exact test and Wilcoxon rank sum
test, as appropriate. P-values <0.05 were considered statistically
significant.
RESULTS
The clinical characteristics of the patients are shown in Table 1.
The median age of the 18 male and 111 female patients was
58 years. The dosing period was for a median 151 days. In
addition to TJ-125, the patients concurrently took other of the 32
Kampo preparations and 22 decoctions (median 1, range 0–3).
The chromatograms of the authentic coumarin (Figure 1A)
and the extract of TJ-125 (Figure 1B) were obtained by HPLC
analysis. The peak, at the retention time of 13.7 min for TJ-125
corresponded to that of coumarin. The coumarin content of the
TJ-125 was separated from the other ingredients. In addition,
the peak for coumarin in the concurrent Kampo medicines and
the cinnamon bark, separated from the other ingredients, was
determined (data not shown). Excellent linearity was observed
over the studied concentration range of the calibration curve,
and the correlation coefficient (r2) was 0.999. With this analytical
method, the limit of detection of coumarin was 0.1 mg/mL.
The coumarin content in the daily dosage of each Kampo
preparation is shown in Table 2. TJ-125 contained 5.63 mg
coumarin per day, the highest content among the 33 Kampo
preparations. Coumarin was not detected in TJ-63, TJ-107, or
TY-026. The mean value for coumarin content as a daily dosage
was 1.43 mg ± 0.20. The coumarin content of 4 g of cinnamon
bark was 12.1 mg. Cinnamon bark had 2.1 times higher coumarin
content than TJ-125. The mean value for coumarin in 1 g of
cinnamon bark was 0.50 mg± 0.06, with TJ-17 having the highest
coumarin per g at 1.65 mg.
The total daily dosage of cinnamon bark when adding that
from TJ-125 to that from the concurrent Kampo medicines
ranged from 4 to 16 g. The median daily intake of coumarin from
the Kampo medicines was 0.113 mg/kg/day, with 98 patients
exceeding the TDI (Table 1). There were six cases (19.4%) of
abnormal change in liver function in the group with less than the
TDI value and 17 (17.3%) in the group with equal to or greater
than the TDI value (Table 3). No significant difference between
these groups was found concerning the incidence of abnormal
change in liver function. Statistically significant differences were
found for body weight, and daily intake of coumarin. The liver
function test values before and after the prescription of TJ-125
are also shown in Table 3. Before the prescription of TJ-125,
γ-GTP was statistically different between the group with less than
the TDI value and the group with equal to or greater than the
TDI value. None of the highest liver function test values after the
prescription of TJ-125 were significantly different between these
groups. Among the 23 patients with an abnormal change in liver
function, AST, ALT, ALP, γ-GTP, T-Bill, and Alb were related to
the poor function of 4, 12, 2, 4, 3, and 7 patients, respectively.
Possible causes of these abnormal changes were diseases other
than hepatopathy for six patients, concomitant drugs other than
the concurrent Kampo medicines for four, life style or age for
three, and problems unrelated to the intake period of Kampo
medicines for ten. None of the cases was related to cinnamon
bark.
DISCUSSION
The TDI of coumarin was established in Europe for protection
against hepatotoxic events. A survey of foods containing
coumarin was conducted to estimate the exposure to coumarin
and to assess its hepatotoxicity. By contrast, no reports of
TABLE 1 | Clinical characteristics of the participants (n = 129).
Sex
Male, n (%) 18 (14.0)
Female, n (%) 111 (86.0)
Age (years) 58 (21–91)
Body weight (kg) 55.0 (38.0–88.7)
Liver function test values (before
prescription of TJ-125)
AST (IU/L) 20 (11–74)
ALT (IU/L) 15 (5–101)
ALP (IU/L) 208 (80–473)
γ-GTP (IU/L) 18 (8–190)
T-Bill (mg/dL) 0.6 (0.2–2.0)
Alb (g/dL) 4.3 (2.4–5.3)
Dosing period (days) 151 (14–1404)
Concurrent Kampo medicines (n) 1 (0–3)
Daily intake of cinnamon bark
contained in Kampo medicines (g/day)
5.0 (4.0–16.0)
Daily intake of coumarin (mg/kg/day) 0.113 (0.049–0.541)
More than the TDI of coumarin, n (%) 98 (76.0)
Incidence of abnormal change in liver
function test values, n (%)
23 (17.8)
Variables expressed as median (range).
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FIGURE 1 | HPLC chromatograms of (A) coumarin (10 mg/mL, standard) and (B) TJ-125. Chromatographic peaks were detected at a wavelength of 273 nm.
The mobile phase consisted of water, acetonitrile and trifluoroacetic acid (750:250:0.5, v/v/v). The flow rate of the mobile phase was 0.5 ml/min. The injection volume
was 10 µL. The column temperature was set at 40◦C. The retention time of coumarin was 13.7 min.
the coumarin content of Kampo medicines or risk assessments
of hepatotoxicity from the coumarin contained in the Kampo
medicines used in clinical practice in Japan have been published.
In the present study, we evaluated the coumarin content of
the Kampo medicines used in clinical practice in Japan to
investigate the association between daily coumarin intake and the
occurrence of hepatotoxicity.
The coumarin content of 33 Kampo preparations and
cinnamon bark was determined by HPLC. The HPLC
methodology for determining the coumarin content of foods
and plants has been published (Biavatti et al., 2004; Sproll et al.,
2008). However, the coumarin content in Kampo medicines
has not been reported. The mobile phase for determining the
coumarin content of Asteraceae is acetonitrile/water (1:1, v/v;
Biavatti et al., 2004). This method made it difficult to separate
the peak of coumarin from other peaks contained in the seven
Kampo preparations that contain bupleurum root (TJ-10, TJ-11,
TJ-12, TJ-114, N10, N11, and N12). Therefore, the mobile phase
in this study was changed to water/acetonitrile/trifluoroacetic
acid (750:250:0.5, v/v/v). We were thus able to measure, under
the same conditions, the quantity of coumarin contained in a
wide range of Kampo preparations.
Of the 33 Kampo preparations surveyed, TJ-125 has the
highest content of coumarin per daily dose (5.63 mg/day;
Table 2). Calculation based on quantitative estimation by HPLC
and the coumarin content per daily dosage from the information
leaflet inserted in the package of 30 Kampo preparations
(excepting TJ-63, 107, and TY-026) were from 0.15 to 5.63 mg.
However, the daily cinnamon bark content in the daily dosage
from the package insert information varied, ranging from 1 to
4 g. The coumarin content in 1 g of cinnamon bark varied
greatly among these Kampo preparations, ranging from 0.05 to
1.65 mg. These results suggest that the coumarin content of
the preparations was not related to the amount of cinnamon
bark used in their production. Previous research has shown that
the coumarin content of cinnamon bark varies by cultivation
site (Sagara et al., 1987). It has been reported that there is as
much as 21 times difference in the coumarin content of 13
cassia cinnamon varieties from different places of cultivation
and that some cinnamons do not contain coumarin (He et al.,
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TABLE 2 | The coumarin content of the daily dosage from the information leaflet inserted in the package of each Kampo preparation and for cinnamon
bark.
Cinnamon bark content
(g/day)
Coumarin content
(mg/day)
Coumarin content
(mg/g of cinnamon bark)
n
Cinnamon bark 4.0 12.07 3.02 1
Keishibukuryogankayokuinin (TJ-125) 4.0 5.63 ± 0.94 1.41 ± 0.24 3
Mokuboito (TJ-36) 3.0 4.00 1.33 1
Keishibukuryogan (TJ-25) 3.0 2.92 ± 0.09 0.97 ± 0.03 3
Ryokeijutsukanto (TJ-39) 4.0 2.80 ± 0.96 0.70 ± 0.24 3
Goreisan (TJ-17) 1.5 2.48 ± 0.07 1.65 ± 0.05 3
Nyoshinsan (TJ-67) 2.0 2.32 1.16 1
Kakkonto (TJ-1) 2.0 2.00 ± 0.07 1.00 ± 0.03 3
Kakkonkajutsubuto (S-07) 2.0 1.80 ± 0.17 0.90 ± 0.09 3
Saireito (TJ-114) 2.0 1.15 0.57 2
Saikokeishikankyoto (N11) 3.0 1.13 0.38 1
Keishininjinto (TJ-82) 4.0 1.09 ± 0.54 0.27 ± 0.14 3
Saikokeishito (N10) 2.5 1.03 0.41 1
Saikokeishito (TJ-10) 2.0 0.86 ± 0.20 0.43 ± 0.10 3
Saikokeishikankyoto (TJ-11) 3.0 0.79 ± 0.05 0.26 ± 0.02 3
Saikokaryukotsuboreito (TJ-12) 3.0 0.69 ± 0.04 0.23 ± 0.01 3
Saikokaryukotsuboreito (N12) 3.0 0.66 0.22 1
Hachimijiogan (TJ-7) 1.0 0.65 ± 0.22 0.65 ± 0.22 3
Keishikaryojutsubuto (SG-18R) 4.0 0.55 ± 0.14 0.14 ± 0.03 3
Keishikaryukotsuboreito (TJ-26) 4.0 0.51 ± 0.23 0.13 ± 0.06 3
Shoseiryuto (TJ-19) 3.0 0.48 ± 0.22 0.16 ± 0.07 3
Keishikajutsubuto (TJ-18) 4.0 0.46 0.11 2
Maoto (TJ-27) 4.0 0.41 ± 0.03 0.10 ± 0.01 3
Kumibinroto (N311) 3.0 0.36 ± 0.02 0.12 ± 0.01 3
Tokikenchuto (TJ-123) 4.0 0.34 ± 0.26 0.08 ± 0.07 3
Shakanzoto (TJ-64) 3.0 0.26 ± 0.05 0.09 ± 0.02 3
Keishito (TJ-45) 4.0 0.26 ± 0.01 0.06 ± 0.00 3
Juzentaihoto (TJ-48) 3.0 0.24 ± 0.04 0.08 ± 0.01 3
Jidabokuippo (TJ-84) 3.0 0.24 ± 0.04 0.08 ± 0.01 3
Hachimigan 1.0 0.22 ± 0.02 0.22 ± 0.02 3
Tokishigyakukagoshuyushokyoto (TJ-38) 3.0 0.15 0.05 1
Goshakusan (TJ-63) 1.0 ND ND 2
Goshajinkigan (TJ-107) 1.0 ND ND 3
Keishikaogito (TY-026) 4.0 ND ND 3
Mean ± SD 1.43 ± 0.20 0.50 ± 0.06
n, number of production lots for HPLC analysis; ND, not detected; The coumarin content and coumarin content included in 1 g of cinnamon bark are shown as mean± SD
for n = 3, mean for n = 2, and the measured value for n = 1.
2005). Another study concluded that there is a difference in the
amount of ephedrine contained in kakkonto and shoseiryuto
extract preparations that depends on the method of extraction
and manufacturing (Nishioka et al., 1996). In the present study,
there is some possibility of influence by differences in the area
the cinnamon bark was cultivated, the method of extraction and
the manufacturing process of each manufacturer, or interaction
of the component galenicals of the Kampo preparations; however,
the cause(s) of the differences in the coumarin content of the
Kampo preparations studied is unclear.
The TDI of coumarin is 5.0 mg/day for an adult weighing
50 kg when calculated as 0.1 mg/kg body weight. The daily
content of coumarin in TJ-125 was 5.63 mg, which made
it the only Kampo preparation among the 33 tested that
exceeded the TDI. The median daily intake of coumarin of the
129 patients tested was 0.113 (0.049–0.541) mg/kg/day, with
98 having more than 0.1 mg/kg/day: more than 75% of the
patients exceeded the TDI. These findings show that patients
administered TJ-125 are routinely exceeding the TDI and that
the risk of liver injury may be increased when TJ-125 is
administrated in combination with other Kampo medicines that
contain cinnamon bark. However, no cases of abnormal liver
function caused by cinnamon bark were observed. Furthermore,
there was no significant difference in the incidence of unusual
changes in the liver function test values between the group of
patients consuming less than the TDI and the group consuming
an amount equal to or greater than the TDI. These results
indicate that there is no association between the intake of the
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TABLE 3 | Daily intake of the coumarin contained in Kampo medicines and the occurrence of liver disease.
Group with less
than the TDI (n= 31)
Group with equal to or
greater than the TDI (n= 98)
P-value
Sex
Male, n (%) 5 (16.1) 13 (13.3) 0.767
Female, n (%) 26 (83.9) 85 (86.7)
Age (years) 56 (27–78) 59 (21–91) 0.362
Body weight (kg) 64 (43–88.7) 53.4 (38–84.8) <0.0001∗
Dosing period (days) 147 (21–869) 152.5 (14–1404) 0.639
Daily intake of coumarin (mg/kg/day) 0.086 (0.049–0.099) 0.124 (0.101–0.541) <0.0001∗
Liver function test values
Before the prescription of TJ-125
AST (IU/L) 20 (11–54) 19.5 (11–74) 0.493
ALT (IU/L) 17 (8–98) 14.5 (5–101) 0.052
ALP (IU/L) 211 (106–355) 206 (81–473) 0.817
γ-GTP (IU/L) 25 (10–190) 16 (8–102) 0.001∗
T-Bill (mg/dL) 0.6 (0.3–1.6) 0.6 (0.2–2.0) 0.876
Alb (g/dL) 4.3 (3.3–4.8) 4.3 (2.4–5.3) 0.827
After the prescription of TJ-125 (highest values)
AST (IU/L) 19 (13–59) 21 (11–98) 0.586
ALT (IU/L) 18 (8–61) 18 (5–126) 0.610
ALP (IU/L) 208 (109–344) 213.5 (15–486) 0.912
γ-GTP (IU/L) 26 (12–120) 20 (7–511) 0.077
T-Bill (mg/dL) 0.7 (0.3–1.3) 0.7 (0.2–1.8) 0.674
Alb (g/dL) 4.2 (3–4.8) 4.2 (2.2–5.1) 0.666
Incidence of abnormal change in liver function test values, n (%) 6 (19.4) 17 (17.3) 0.792
Variables expressed as median (range). Sex and incidence of abnormal change in liver function test values were evaluated by Fisher’s exact test and the others were
evaluated by Wilcoxon rank sum test. ∗Significantly different between the group with less than the TDI and the group with equal to or greater than the TDI (P < 0.05).
coumarin found in Kampo medicines and the occurrence of liver
injury.
TJ-125 is a mixture of six constituent herbs: cinnamon
bark, moutan bark, Paeonia lactiflora, peach kernel, Poria
sclerotium, and coix seed. These herbs are not included
in the traditional Chinese herbal medicines that have been
reported to cause hepatotoxicity (Teschke et al., 2015). It is
known that there are 10 chemical components other than
coumarin in TJ-25, and that they are also included in TJ-
125 (Seto et al., 2000). No hepatotoxicity by these ingredients
has been reported. Moutan bark has been shown to have
a protective effect against cytotoxicity in human liver cells
(Shon and Nam, 2002). The paeonol in moutan bark protects
against epirubicin-induced hepatotoxicity (Wu et al., 2016).
Additionally, the extract of Paeonia lactiflora and Astragalus
membranaceus has a protective effect on carbon tetrachloride-
induced liver fibrosis in rats and on Bacillus Calmette-Gueìrin
and lipopolysaccharide induced liver injury in mice (Sun
et al., 2007, 2008). The coumarin contained in cinnamon bark
might by itself induce liver disease, but the hepatotoxicity of
coumarin may be suppressed by other component galenicals.
In order to clarify components that might affect liver function,
further animal model experiments using purified compounds
are necessary. Our results indicate that consumption of
the coumarin contained in the Kampo medicines used in
clinical practice that exceeds the TDI has little effect on
hepatotoxicity.
A limitation to this study is that none of the patients were
prescribed cinnamon bark only. It is possible that cinnamon bark
interacts with other herbal medicines. Further studies are needed
about the interaction between cinnamon bark and other Kampo
medicines that do not contain coumarin. Moreover, the coumarin
content of the 22 decoctions was calculated by the coumarin
content of the constituent cinnamon bark, but the content may
differ greatly when used in combination with other constituents.
Also, it has been reported that only a small percentage of the
Caucasian population is sensitive to coumarin (Abraham et al.,
2010). The coumarin-related hepatotoxic incidence in Japan and
the hepatotoxic incidence rate caused by cinnamon bark are not
known. Therefore, the number of patients studied, 129, may be
too small to provide conclusive results. In addition, because the
present study was of retrospective in design, the amount of data
available for analysis in the electronic medical record was limited.
We estimated the cause of abnormal liver function change by the
electronic medical record and by inquiry to the doctor in charge
of the patient. However, we were not able to obtain the records on
the medication compliance of the patients, medicines purchased
over the counter at a pharmacy, or medicines prescribed by other
hospitals. These factors may be related to the changes of liver
function. There is also a possibility that some cases of liver injury
were missed because liver function testing was not routinely
performed during follow-up. Finally, this study also showed a bias
toward the number of women because TJ-125 is often prescribed
to patients with gynecological diseases. Thus further investigation
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that includes more patients will be required to provide more
detailed information.
CONCLUSION
Our evaluation of the coumarin content of Kampo medicines
derived from cinnamon bark and their risk for hepatotoxicity in
clinical practice showed that many of the patients prescribed TJ-
125 had coumarin intake exceeding the TDI. However, no cases of
abnormal liver function caused by cinnamon bark were observed.
Our results suggest that ingestion of the coumarin contained in
Kampo medicines that exceeds the TDI is not associated with
hepatotoxicity and that Kampo medicines may be safely used in
clinical practice, without concern for exceeding the TDI.
AUTHOR CONTRIBUTIONS
All authors listed, have made substantial, direct and
intellectual contribution to the work, and approved it for
publication.
ACKNOWLEDGMENTS
We thank Mr. Hideaki Takechi of Akari Pharmacy and the
laboratory members of the Department of Clinical Pharmacy and
Pharmaceutical Care for their comments. We are grateful to all
of the patients who gave their valuable time to participate in our
study.
REFERENCES
Abraham, K., Wöhrlin, F., Lindtner, O., Heinemeyer, G., and Lampen, A. (2010).
Toxicology and risk assessment of coumarin: focus on human data. Mol. Nutr.
Food Res. 54, 228–239. doi: 10.1002/mnfr.200900281
BfR (Federal Institute for Risk Assessment) (2006). Consumers, who eat a lot of
cinnamon, currently have an overly high exposure to coumarin. BfR Health
Assessment No. 043/2006. Berlin: Federal Institute for Risk Assessment.
Biavatti, M. W., Koerich, C. A., Henck, C. H., Zucatelli, E., Martineli, F. H.,
Bresolin, T. B., et al. (2004). Coumarin content and physicochemical profile of
Mikania laevigata extracts. Z. Naturforsch. C. 59, 197–200. doi: 10.1515/znc-
2004-3-412
Brancheau, D., Patel, B., and Zughaib, M. (2015). Do cinnamon supplements cause
acute hepatitis? Am. J. Case Rep. 16, 250–254. doi: 10.12659/AJCR.892804
Casley-Smith, J. R., Morgan, R. G., and Piller, N. B. (1993a). Treatment of
lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N. Engl. J.
Med. 329, 1158–1163. doi: 10.1056/NEJM199310143291604
Casley-Smith, J. R., Wang, C. T., and Zi-hai, C. (1993b). Treatment of filarial
lymphoedema and elephantiasis with 5,6-benzo-alpha-pyrone (coumarin).
BMJ. 307, 1037–1041. doi: 10.1136/bmj.307.6911.1037
Cholerton, S., Idle, M. E., Vas, A., Gonzalez, F. J., and Idle, J. R. (1992). Comparison
of a novel thin-layer chromatographic-fluorescence detection method with
a spectrofluorometric method for the determination of 7-hydroxycoumarin
in human urine. J. Chromatogr. 575, 325–330. doi: 10.1016/0378-4347(92)
80166-N
Egan, D., O’Kennedy, R., Moran, E., Cox, D., Prosser, E., and Thornes, R. D.
(1990). The pharmacology, metabolism, analysis, and applications of coumarin
and coumarin-related compounds. Drug Metab. Rev. 22, 503–529. doi:
10.3109/03602539008991449
Hayashi, S., Shibutani, S., Okubo, H., Shimogawara, T., Ichinose, T., Ito, Y., et al.
(2014). Examination of clinical efficacy of keishibukuryogan on non-specific
complaints associated with varicose veins of the lower extremity. Ann. Vasc.
Dis. 7, 266–273. doi: 10.3400/avd.oa.14–00055
Hazleton, L. W., Tusing, T. W., Zeitlin, B. R., Thiessen, Jr. R., and Murer, H. K.
(1956). Toxicity of coumarin. J. Pharmacol. Exp. Ther. 118, 348–358.
He, Z. D., Qiao, C. F., Han, Q. B., Cheng, C. L., Xu, H. X., Jiang, R. W., et al. (2005).
Authentication and quantitative analysis on the chemical profile of cassia bark
(cortex cinnamomi) by high-pressure liquid chromatography. J. Agric. Food
Chem. 53, 2424–2428. doi: 10.1021/jf048116s
Itoh, T., Terasawa, K., Kohta, K., Shibahara, N., Tosa, H., and Hiyama, Y. (1992).
Effects of Keishi-bukuryo-gan and Trapidil on the microcirculation in patients
with cerebro-spinal vascular disease. J. Trad. Med. 9, 40–46.
Khan, A., Safdar, M., Ali Khan, M. M., Khattak, K. N., and Anderson, R. A. (2003).
Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes
Care 26, 3215–3218. doi: 10.2337/diacare.26.12.3215
Lake, B. G., Evans, J. G., Lewis, D. F., and Prce, R. J. (1994). Comparison
of the hepatic effects of coumarin, 3,4-Dimethylcoumarin, dihydrocoumarin
and 6-methylcoumarin in the rat. Food. Chem. Toxicol. 32, 743–751. doi:
10.1016/S0278-6915(09)80007-0
Lake, B. G., Gray, T. J., Evans, J. G., Lewis, D. F., Beamand, J. A., and
Hue, K. L. (1989). Studies on the mechanism of coumarin-induced toxicity
in rat hepatocytes: comparison with dihydrocoumarin and other coumarin
metabolites. Toxicol. Appl. Pharmacol. 97, 31l–323. doi: 10.1016/0041-
008x(89)90336-0
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Rooke, T. W., Quella, S. K.,
Novotny, P., et al. (1999). Lack of effect of coumarin in women with
lymphedema after treatment for breast cancer. N. Engl. J. Med. 340, 346–350.
doi: 10.1056/NEJM199902043400503
Ministry of Health, Labour and Welfare, Japan (2011). Japanese Pharmacopoeia,
16th Edn. Tokyo: Ministry of Health, Labour and Welfare of Japan, 1679–1681.
Nishioka, Y., Miyamura, M., Kyotani, S., and Ono, M. (1996). A study on ethical
kampo formulation medicines: contents of active ingredients of ethical kakkon-
to and sho-seiryu-to extract preparations. Journal of the Nippon Hosp. Pharm.
Assoc. 22, 473–481.
Okamura, N., Miki, H., Ishida, S., Ono, H., Yano, A., Tanaka, T.,
et al. (1999). Simultaneous determination of baicalin, wogonoside,
baicalein, wogonin, berberine, coptisine, palmatine, jateorrhizine and
glycyrrhizin in Kampo medicines by ion-pair high-performance liquid
chromatography. Biol. Pharm. Bull. 22, 1015–1021. doi: 10.1248/bpb.
22.1015
Peamkrasatam, S., Sriwatanakul, K., Kiyotani, K., Fujieda, M., Yamazaki, H.,
Kamataki, T., et al. (2006). In vivo evaluation of coumarin and nicotine as
probe drugs to predict the metabolic capacity of CYP2A6 due to genetic
polymorphism in Thais. Drug Metab. Pharmacokinet. 21, 475–484. doi:
10.2133/dmpk.21.475
Pearce, R., Greenway, D., and Parkinson, A. (1992). Species differences and
interindividual variation in liver microsomal cytochrome P450 2A enzymes:
effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem.
Biophys. 298, 211–225. doi: 10.1016/0003-9861(92)90115-D
Pelkonen, O., Rautio, A., Raunio, H., and Pasanen, M. (2000). CYP2A6: a
human coumarin 7-hydroxylase. Toxicology 144, 139–147. doi: 10.1016/S0300-
483X(99)00200-0
Sagara, K., Oshima, T., Yoshida, T., Tong, Y. Y., Zhang, G., and Chen,
Y. H. (1987). Determination of Cinnamomi Cortex by high-performance
liquid chromatography. J. Chromatogr. 409, 365–370. doi: 10.1016/S0021-
9673(01)86814-X
Sato, Y., Uno, T., Oyun, K., Koide, T., Tamagawa, T., and Bolin, Q. (2006). Role
of herbal medicine (Kampo formulation) on the prevention and treatment of
diabetes complications. J. Trad. Med. 23, 185–195.
Seto, T., Hamano, T., Shioda, H., Kamimura, H., and Onishi, K. (2000). Difference
of components according to dosage forms and change of constituents in the
process of preparing extract on Kampo hozai Keishi-bukuryo-gan. J. Tradit.
Med. 17, 80–86.
Shilling, W. H., Crampton, R. F., and Longland, R. C. (1969). Metabolism of
coumarin in man. Nature 221, 664–665. doi: 10.1038/221664b0
Shon, Y. H., and Nam, K. S. (2002). Protective effect of moutan cortex extract on
acetaminophen-induced cytotoxicity in human Chang liver cells. Biol. Pharm.
Bull. 25, 1427–1431. doi: 10.1248/bpb.25.1427
Frontiers in Pharmacology | www.frontiersin.org 8 June 2016 | Volume 7 | Article 174
fphar-07-00174 June 16, 2016 Time: 13:1 # 9
Iwata et al. Hepatotoxicity of Keishibukuryogankayokuinin Containing Coumarin
Sproll, C., Ruge, W., Andlauer, C., Godelmann, R., and Lachenmeier,
D. W. (2008). HPLC analysis and safety assessment of coumarin
in foods. Food Chem. 109, 462–469. doi: 10.1016/j.foodchem.2007.
12.068
Sun, W. Y., Wei, W., Gui, S. Y., Wu, L., and Wang, H. (2008). Protective
effect of extract from Paeonia lactiflora and Astragalus membranaceus against
liver injury induced by bacillus Calmette-Guérin and lipopolysaccharide in
mice. Basic Clin. Pharmacol. Toxicol. 103, 143–149. doi: 10.1111/j.1742-
7843.2008.00243.x
Sun, W. Y., Wei, W., Wu, L., Gui, S. Y., and Wang, H. (2007). Effects and
mechanisms of extract from Paeonia lactiflora and Astragalus membranaceus
on liver fibrosis induced by carbon tetrachloride in rats. J. Ethnopharmacol. 112,
514–523. doi: 10.1016/j.jep.2007.04.005
Terawaki, K., Noguchi, M., Yuzurihara, M., Omiya, Y., Ikarashi, Y., and Kase, Y.
(2015). Keishibukuryogan, a traditional Japanese medicine, inhibits platelet
aggregation in Guinea Pig whole blood. Evid. Based Complement. Alternat. Med.
2015, 295706. doi: 10.1155/2015/295706
Teschke, R., Zhang, L., Long, H., Schwarzenboeck, A., Schmidt-Taenzer, W.,
Genthner, A., et al. (2015). Traditional Chinese Medicine and herbal
hepatotoxicity: a tabular compilation of reported cases. Ann. Hepatol. 14, 7–19.
Wang, Y. H., Avula, B., Nanayakkara, N. P., Zhao, J., and Khan, I. A. (2013).
Cassia cinnamon as a source of coumarin in cinnamon-flavored food and food
supplements in the United States. J. Agric. Food Chem. 61, 4470–4476. doi:
10.1021/jf4005862
Wu, J., Xue, X., Zhang, B., Jiang, W., Cao, H., Wang, R., et al. (2016). The
protective effects of paeonol against epirubicin-induced hepatotoxicity in 4T1-
tumor bearing mice via inhibition of the PI3K/Akt/NF-kB pathway. Chem. Biol.
Interact. 244, 1–8. doi: 10.1016/j.cbi.2015.11.025
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Iwata, Kainuma, Kobayashi, Kubota, Sugawara, Uchida, Ozono,
Yamamuro, Furusyo, Ueda, Tahara and Shimazoe. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 9 June 2016 | Volume 7 | Article 174
